View abstract

Cet abstract a été assigné à session Poster session
TitreTreatment of taxane (docetaxel)-induced maculopathy with oral acetazolamide
Abstract Nr.1063
ButCystic macular edema without leakage on fluorescein angiography (FFA) is a very rare complication of systemic chemotherapy with taxanes. We describe a patient who developed this phenomenon and demonstrate complete resolution with cessation of the drug in combination with oral acetazolamide.
MéthodesA 74-year-old man with a history of non-small-cell lung carcinoma treated with Docetaxel (Taxotere) presented to our department with a 1-month history of bilateral progressive visual loss. He underwent a complete ophthalmologic work-up.
RésultatsAt presentation, BCVA was limited to 2/10 in both eyes. Fundoscopy and OCT revealed bilateral extensive intra- and subretinal fluid spread over the posterior pole towards the midperiphery in the absence of other pathological findings. Despite the significant amount of cystic spaces on OCT, FFA remarkably showed no leakage of dye. The chemotherapeutic Docetaxel(Taxotere), was identified as a potential inciting agent, and suspended in collaboration with the oncologist. Acetazolamide 250 mg t.i.d. was added to hasten recovery. The next 10 weeks, BCVA gradually improved to 6/10 in the RE and 8/10 in the LE with complete resolution of intra- and subretinal fluid and remained stable 1 month after cessation of treatment.
ConclusionCystic macular edema without leakage is a rarely documented but significant side effect of docetaxel and other taxane chemotherapeutics. Acetazolamide may be useful to hasten resorption of fluid and improve quality of life.
Auteur 1
NomDERVEAUX
InitialesT
InstitutDept. of Ophthalmology, Ghent University Hospital
VilleGhent
Auteur 2
NomDE KESEL
InitialesR
InstitutDept. of Ophthalmology, AZ Jan Palfijn
VilleGhent
Auteur 3
NomSAMYN
InitialesI
InstitutDept. of Oncology, AZ Jan Palfijn
VilleGhent
Auteur 4
NomDE ZAEYTIJD
InitialesJ
InstitutDept. of Ophthalmology, Ghent University Hospital
VilleGhent
top ^